IMCR Immunocore Holdings plc ADRs

Immunocore is a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$29.49  -0.88 (-2.90%)
As of 05/24/2022 15:59:58 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  02/04/2021
Outstanding shares:  43,862,850
Average volume:  219,977
Market cap:   $1,325,096,699
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   8.16
PS ratio:   25.88
Return on equity:   -72.64%
Net income %:   -291.26%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy